Immix Biopharma (NASDAQ:IMMX) Now Covered by Morgan Stanley

Morgan Stanley initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued an overweight rating and a $20.00 price objective on the stock.

Several other brokerages have also commented on IMMX. Wall Street Zen lowered shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Mizuho assumed coverage on Immix Biopharma in a report on Monday, February 9th. They issued an “outperform” rating and a $14.00 price objective for the company. Citizens Jmp initiated coverage on Immix Biopharma in a research report on Monday, March 9th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $16.25.

Immix Biopharma Stock Up 4.0%

Shares of NASDAQ:IMMX opened at $8.91 on Wednesday. The company’s 50-day moving average price is $7.62 and its 200 day moving average price is $5.18. The company has a market cap of $471.87 million, a PE ratio of -11.57 and a beta of 0.25. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $11.61.

Institutional Trading of Immix Biopharma

A number of large investors have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP acquired a new position in Immix Biopharma in the second quarter worth approximately $52,000. Vanguard Group Inc. lifted its position in shares of Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after acquiring an additional 31,625 shares during the last quarter. Tocqueville Asset Management L.P. lifted its position in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after acquiring an additional 10,950 shares during the last quarter. Imprint Wealth LLC bought a new stake in shares of Immix Biopharma during the 3rd quarter worth $141,000. Finally, Citadel Advisors LLC bought a new stake in shares of Immix Biopharma during the 3rd quarter worth $188,000. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.